$NVO
AI 分析生成于 May 13, 2026
AI Score
Buy$NVO
Novo Nordisk A/S
$NVONYSEHealthcareMega-Cap
Novo Nordisk is a global healthcare company specializing in diabetes care and obesity treatment, maker of blockbuster GLP-1 drugs Ozempic, Wegovy, and Rybelsus.
Market Cap
$480.0B
Revenue (TTM)
$42.6B
+26.0%
Net Income (TTM)
$15.8B
+28.0%
EPS (TTM)
$3.52
P/E Ratio
32.0
Dividend Yield
1.2%
52-Week Range
$80-$148
Beta
0.82
Dimension Scores
Fundamental
82Technical
72Sentiment
76Risk / Reward
74Momentum
78Financial Health
Profitability
87strong
Growth
81strong
Liquidity
82strong
Solvency
84strong
Efficiency
80strong
Valuation, technical analysis, investment thesis, risk assessment and more for $NVO
Free · No credit card required
免责声明: AI 生成的分析仅供教育参考,不构成投资建议。请始终咨询合格的理财顾问。